Real-world outcomes and direct care cost before and after elexacaftor/tezacaftor/ivacaftor initiation in commercially insured members with cystic fibrosis

BACKGROUND: Cystic fibrosis (CF) is a chronic, progressive genetic disease caused by mutations in the CF transmembrane conductance regulator (CFTR) gene resulting in a dysfunctional CFTR protein. Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a triple combination oral drug therapy with an annual...

Descripción completa

Detalles Bibliográficos
Autores principales: Marshall, Landon Z, Espinosa, Rachel, Starner, Catherine I, Gleason, Patrick P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388005/
https://www.ncbi.nlm.nih.gov/pubmed/37276039
http://dx.doi.org/10.18553/jmcp.2023.29.6.599

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10388005/
https://www.ncbi.nlm.nih.gov/pubmed/37276039
http://dx.doi.org/10.18553/jmcp.2023.29.6.599

Ejemplares similares